target menu
 

Agami, Reuven

Back to List

 

Reuven-Agami_200xNAME Reuven Agami
POSITION TITLE Professor; Head of a division.
EDUCATION/TRAINING (Master, PhD, Clinical Specialization … only mention Institution, Degree, Year and Field)
1991-1993: Master at the department of molecular genetics and virology, The Weizmann Institute of Science, Rehovot, Israel.
1993 - 1999: PhD at the department of molecular genetics and virology, The Weizmann Institute of Science, Rehovot, Israel.

 

 

A. Positions and Honors:

I. Positions and employment
1999 - 2001: Post-doctoral fellowship at the Division of Molecular Carcinogenesis, The Netherlands Cancer Institute, Amsterdam,
2001 - 2005: Assistant professor at the Division of Tumor Biology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
2005 - 2008: Associated professor at the Division of Tumor Biology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
Since June 2008: Full Professor, Head of Division of Gene Regulation, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
Since June 2014: Head of Division of Biological Stress Response, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
II. Other relevant experience and professional memberships
Editorial board of EMBO journal, EMBOreports journal, and Cell Cycle journal.
Reviewer to Cell, Nature, Science, EMBO J, and more.
Organized international meeting on ncRNAs and epigenetics Amsterdam 2011.

III. Honors and awards
1999: EMBO long-term fellowship.
2001: Netherlands Cancer Institute (AVL) award.
2002: Elected fellow of the central for biomedical genetics (CBG).
2002: Holding patent on pSUPER- vector based RNAi technology.
2004: European Young Investigator Award (EURYI).
2004: VIDI grant.
2004: EMBO young investigator award.
2006: Elected member of the young academy (DJA-KNAW).
2006: Patented the miRVec-miRNA expression technology.
2007: Awarded The Dr. Joseph Steiner Prize, Switzerland 2007 in Biel.
2008: Elected member of EMBO.
2008: Awarded ERC starting project on microRNA regulation.
2009: Elected member of the central for biomedical genetics (CBG).
2009: Professor at the Genetics and Pathology departments of Erasmus Medical Center, Rotterdam
2010: ESCI Award Winner 2010, Basic/Translational Research.
2011: Awarded NWO-VICI grant on regulation of translation in cancer.
2013: Awarded ERC-advanced project on enhancer RNAs.


Top publications:

1. Rooijers K, Loayza-Puch F, Nijtmans LG, Agami R.  Ribosome profiling reveals features of normal and disease-associated mitochondrial translation. Nat Commun. 2013 Dec 3;4:2886. IF: 10.7

2. Melo, C.A., Drost, J., Wijchers, P.J., van de Werken, H., de Wit, E., Vrielink, J.A., Elkon, R., Melo, S.A., Leveille, N., Kalluri, R., de Laat, W., and Agami, R. eRNAs Are Required for p53-Dependent Enhancer Activity and Gene Transcription. Molecular Cell 2013 Feb 7;49(3):524-35. IF: 15.2

3. Jenal, M., Elkon, R., Loayza-Puch1, F., van Haaften, G., Kühn, U., Menzies, F. M., Oude Vrielink, J. A. Bos, A. J., Drost, J., Rooijers, K., Rubinsztein, D. C., and Agami R. (2012). The Poly(A)-Binding Protein Nuclear 1 (PABPN1) suppresses alternative cleavage and polyadenylation sites. Cell. Apr 27;149(3):538-53. IF: 33

4. Léveillé, N., Elkon, R., Davalos, V., Manoharan, V., Hollingworth, D., Oude Vrielink, AF. And Agami, R. (2011). Selective inhibition of miRNA accessibility by RBM38 is required for p53 activity. Nature Communications. 25, 513-519. IF: 10.7

5. Drost, J., Mantovani, F., Tocco, F., Elkon, R., Comel, A., Holstege, H., Kerkhoven, K., Jonkers, J., Voorhoeve, P. M., Agami, R., and Del Sal, G. BRD7 is a candidate tumour suppressor gene required for p53 function. On line 15 March 2010 Nature cell Biology. IF: 20

6. Huang, Q., Gumireddy, K., Schrier, M., le Sage, C., Nagel, R., Nair, S., Egan, D. A., Li, A., Huang, G., Klein-Szanto, A. J., Pure, E. Agami, R. (2008). The microRNAs miR-373 and miR-520c promote tumour invasion and metastasis. Nature Cell Biology. 10, 202-210.  IF: 20

7. Kedde, M., Strasser, M. J., Boldajipour, B., Vrielink, J. A., Slanchev, K., le Sage, C., Nagel, R., Voorhoeve, P. M., van Duijse, J., Orom, U. A., Lund, A. H., Perrakis, A., Raz, E. Agami, R. (2007). RNA-binding protein Dnd1 inhibits microRNA access to target mRNA. Cell. 131, 1273-1286. IF: 33

8. Voorhoeve P. M le Sage C. , Schrier M., Gillis A. J.M., Stoop H., Nagel R. Liu Y., van Duijse J., Drost J., Griekspoor A., Zlotorynski E., Yabuta N., De Vita G., Nojima H., Looijenga L. H.J. and Agami R. (2006). A genetic screen implicates miRNA-372 and miRNA-373 as oncogenes in testicular germ cell tumors. Cell. 124, 1169-1181. IF: 33

9. Kolfschoten I, Leeuwen B, Berns K, Bijersbergen R, Bernards R, Voorhoeve PM, and Agami R, (2005). A genetic screen identifies PITX1 as a suppressor of RAS activity and tumorigenicity. Cell. 121(6):849-858. IF: 313

10. Brummelkamp, T. R., Bernards, R. and Agami, R. (2002). A system for stable expression of short interfering RNAs in mammalian cells. Science. 295. IF: 31



Description of research projects:
The Agami lab has a long-standing interest in RNA-related gene regulation topics, with the main focus on their impact on cancer and other human genetic diseases. In the past years we were the first to develop genetic tools to stably suppress gene expression in order to study tumorigenesis by various cellular models, and to investigate the causal role of microRNAs in cancer using functional genetic approaches.

More recently we expanded our toolbox to innovative techniques for genome-wide studying of mRNA isoforms, non-coding RNAs functions, and protein translation control, as well as their impact on cell behavior and human health. The lab combines novel bioinformatics and experimental work.   

Website: http://research.nki.nl/agamilab/

 


Keywords: Cancer, RNAi, microRNAs, Long noncoding RNAs, enhancer RNAs, Alternative polyadenylation, and protein translation.